US20110301053A1 - Methods for Diagnosing, Staging, Predicting Risk for Developing and Identifying Treatment Responders for Rheumatoid Arthritis - Google Patents

Methods for Diagnosing, Staging, Predicting Risk for Developing and Identifying Treatment Responders for Rheumatoid Arthritis Download PDF

Info

Publication number
US20110301053A1
US20110301053A1 US13/102,683 US201113102683A US2011301053A1 US 20110301053 A1 US20110301053 A1 US 20110301053A1 US 201113102683 A US201113102683 A US 201113102683A US 2011301053 A1 US2011301053 A1 US 2011301053A1
Authority
US
United States
Prior art keywords
concentration
totmmp
healthy volunteer
less
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/102,683
Other languages
English (en)
Inventor
John Allan Todd
Quynh Anh Thuc Lu
Sara Jane Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Singulex Inc
Original Assignee
Singulex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singulex Inc filed Critical Singulex Inc
Priority to US13/102,683 priority Critical patent/US20110301053A1/en
Assigned to SINGULEX, INC. reassignment SINGULEX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LU, QUYNH ANH THUC, TODD, JOHN ALLAN, LE, SARA JANE
Publication of US20110301053A1 publication Critical patent/US20110301053A1/en
Priority to US14/476,820 priority patent/US10288623B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/34—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Corynebacterium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Definitions

  • RA Rheumatoid Arthritis
  • Th1 CD4+ T helper cell-induced; interferon-gamma, for example, is produced, which activates the bactericidal activities of macrophages and induces B-cells to make opsonizing (coating) antibodies, leading to cellular immunity
  • Th2 CD4+ T helper cell-induced; interleukin 4, for example, is released, which results in the activation of B-cells to make neutralizing antibodies, leading to humoral immunity
  • IL-17a a proinflammatory cytokine
  • IL-17a a proinflammatory cytokine
  • subject IL-17A, IL-17A/F and/or IL-17F biomarker concentrations are compared to average biomarker concentrations for healthy volunteers, and in aspects age- and/or gender-matched healthy volunteers, to predict whether they have a greater than normal risk of developing RA or other inflammatory disorders.
  • additional biomarker e.g., IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI
  • concentrations are determined and utilized to predict whether a subject has a greater than normal risk of developing RA or other inflammatory disorders.
  • values are used, and in others comparisons to average biomarker concentrations for healthy volunteers, and in aspects age- and/or gender-matched volunteers are utilized.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorders in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and/or IL-17F greater than about 0.18 pg/ml, 1.35 pg/ml and 116 pg/ml, respectively, the subject has an increased likelihood of developing RA or other inflammatory disorders.
  • subject IL-17A, IL-17A/F and/or IL-17F biomarker concentrations are compared to average biomarker concentrations for healthy volunteers, and in aspects age- and/or gender-matched healthy volunteers, to determine the likelihood of the subject developing RA.
  • additional biomarker e.g., IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI
  • concentrations are determined and utilized to determine the likelihood of the subject developing RA or other inflammatory disorders.
  • values are used, and in others comparisons to average biomarker concentrations for healthy volunteers, and in aspects age- and/or gender-matched volunteers are utilized.
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the RA patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the RA or other inflammatory disorder patient, obtaining a second sample from the RA patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the RA patient has a first concentration of IL-17A, IL-17A/F and/or IL-17F greater than about 0.18 pg/ml, 1.35 pg/m
  • the disclosure provides methods for predicting the rate of inflammatory disease progression in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the concentration of none, one or more than one of IL-17A is greater than 0.18 pg/ml, IL-17-F is greater than 116 pg/ml, or IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one, one or more or at least two of IL-1 ⁇ is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, or IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a slow rate, medium rate or high rate of inflammatory disease progression.
  • the disclosure provides methods for predicting the likelihood of inflammatory disease remission in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the concentration of none, one or more than one of IL-17A is greater than 0.18 pg/ml, IL-17-F is greater than 116 pg/ml, or IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one, one or more or at least two of IL-1 ⁇ is less than 1.1.
  • totMMP-9 is less than 5.0 ng/ml, or IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a high likelihood, medium likelihood or a low likeihood of inflammatory disease remission.
  • the disclosure provides methods for determining the severity of inflammatory disease in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the concentration of one or more of IL-17A is greater than 0.18 pg/ml, IL-17-F is greater than 116 pg/ml, or IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of none, one, one or more, or two or more or one of IL-1 ⁇ is less than 1.1.
  • pg/ml, totMMP-9 is less than 5.0 ng/ml
  • IL-6 is greater than 1.0 pg/ml
  • the subject is determined to have mild, moderate or severe inflammatory disease.
  • the inflammatory disease is selected from the group consisting of RA, Crohn's Disease, IBD, ulcerative colitis, psoriasis, and COPD.
  • subject IL-17A, IL-17A/F and/or IL-17F biomarker concentrations are compared to average biomarker concentrations for healthy volunteers, and in aspects age- and/or gender-matched healthy volunteers, to identify RA or other inflammatory disorder patients who respond to therapy.
  • additional biomarker e.g., IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI
  • concentrations are determined and utilized to identify RA or other inflammatory disorder patients who respond to therapy.
  • values are used, and in others comparisons to average biomarker concentrations for healthy volunteers, and in aspects age- and/or gender-matched volunteers are utilized.
  • the disclosure provide method for determining inflammatory disease in a patient.
  • the method includes detecting the concentration of more or more the following markers in a patient sample: IL-17A, IL-17F, IL-17A/F, IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, and cTnI, comparing the level of the one or more markers to the level in a normal population of healthy volunteers; and determining that the patient has inflammatory disease when the concentration of IL-17A, IL-17F, IL-17A/F, IL-6, or cTnI are elevated relative to the normal population, or totMMP-9, proMMP-9, or IL-1 ⁇ are decreased relative to the normal population.
  • the disease is RA and the one or more markers include the combination of IL-17F & IL-17A, the combination of IL-17A and IL-17 A/F, or the combination of IL-17F and IL-17 A/F.
  • FIG. 1 illustrates various biomarker levels in RA patients versus healthy volunteers.
  • the three hash marks through each data set represent mean and one standard deviation above and below the mean. Concentrations of several markers are significantly elevated or attenuated in RA patients (P-values are indicated).
  • FIG. 2 provides a larger-scale view of select results illustrated in FIG. 1 .
  • the three hash marks through each data set represent mean and upper and lower quartile divisions (rather than mean and one standard deviation above and below the mean).
  • FIG. 3 illustrates the heretofore unknown importance of the IL-17A, IL-17F, IL-17A/F heterodimer in RA biology. Only 6% of RA patients in the sample had neither IL-17A nor IL-17F present at elevated concentrations over HV. All RA patients had at least one of IL-17A, IL-17F, and IL-17A/F heterodimer present at elevated concentrations over HV.
  • FIG. 4 shows box plots of the markers that best classify RA along with a box plot for TNF ⁇ .
  • FIG. 5 shows that the combination of IL-17F & IL-17A as biomarkers for RA were 100% predictive of disease.
  • FIG. 6 shows that the combination of IL-17A and IL-17 A/F as biomarkers for RA perform very well in predicting disease.
  • FIG. 7 shows that the combination of IL-17F and IL-17 A/F as biomarkers for RA perform very well in predicting disease.
  • the term “subject” refers to a mammal that can be afflicted by a rheumatoid arthritis, but may or may not have such a disease.
  • the terms “subject” and “patient” are used herein interchangeably in reference.
  • the subject is a human.
  • sample is taken broadly to include any sample suitable for the methods described herein.
  • the sample is a biological sample such as, for example, a biological fluid.
  • biological fluids can include, without limitation, bronchoalveolar lavage fluid (BAL), blood, serum, plasma, urine, nasal swab, cerebrospinal fluid, pleural fluid, synovial fluid, peritoneal fluid, amniotic fluid, gastric fluid, lymph fluid, interstitial fluid, tissue homogenate, cell extracts, saliva, sputum, stool, physiological secretions, tears, mucus, sweat, milk, semen, seminal fluid, vaginal secretions, fluid from ulcers and other surface eruptions, blisters, and abscesses, and extracts of tissues including biopsies of normal, malignant, and suspect tissues or any other constituents of the body which may contain the target particle of interest.
  • Other similar specimens such as cell or tissue culture or culture broth are also of interest.
  • the sample is a biological sample such as, for example, a
  • the term “healthy volunteer average concentrations” refers to the average concentration of the various biomarkers described herein for at least two subjects who do not have RA (e.g., HV).
  • average concentration values are calculated from biomarker concentrations measured in larger groups of HVs.
  • Healthy volunteer average concentrations are provided herein, but one of skill in the art may also measure biomarker concentrations in one or more populations of subjects lacking RA utilizing an apparatus capable of sensitively measuring the concentrations of biomarkers described herein and calculating the average values for each biomarker in such HV populations.
  • the term “therapy” refers to the administration of any medical treatment (e.g., pharmaceuticals) or interventional treatment (e.g., surgery) to affect RA or the biomarkers relevant to RA described herein.
  • the term “substantially the same as” refers to ⁇ about 25%, ⁇ about 20%, ⁇ about 15%, ⁇ about 10%, ⁇ about 5%, ⁇ about 3%, ⁇ about 2%, or ⁇ about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ⁇ about 20%, ⁇ about 15%, ⁇ about 10%, or ⁇ about 5%, ⁇ about 3%, ⁇ about 2%, or ⁇ about 1% of the healthy volunteer average concentrations of a biomarker.
  • substantially the same as refers to ⁇ about 15%, ⁇ about 10%, ⁇ about 5%, ⁇ about 3%, ⁇ about 2%, or ⁇ about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ⁇ about 10%, ⁇ about 5%, ⁇ about 3%, ⁇ about 2%, or ⁇ about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ⁇ about 5%, ⁇ about 3%, ⁇ about 2%, or ⁇ about 1% of the healthy volunteer average concentrations of a biomarker.
  • substantially the same as refers to ⁇ about 3%, ⁇ about 2%, or ⁇ about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ⁇ about 2%, or ⁇ about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ⁇ about 1% of the healthy volunteer average concentrations of a biomarker.
  • CV refers to the coefficient of variance. In some aspects “substantially the same as” refers to ⁇ about 10%, ⁇ about 5%, ⁇ about 3%, ⁇ about 2%, or ⁇ about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ⁇ about 5%, ⁇ about 3%, ⁇ about 2%, or ⁇ about 1% of the healthy volunteer average concentrations of a biomarker.
  • average CV refers to average of the coefficient of variance obtained for all samples tested in triplicate.
  • LoD refers to the limit of detection, defined as 2 standard deviations above the zero calibrator.
  • LLoQ refers to the lower limit of quantification, defined from data generated off of the standard curve. Specifically, the back interpolated values of standards in triplicate provide CVs ⁇ 20% and a bias ⁇ 20% of the expected values.
  • inflammatory disorder and “inflammatory disease” refer to any of a number of conditions in which inflammation is increased over normal subjects.
  • Non-limiting examples of inflammatory disorders are rheumatoid arthritis, Crohn's Disease, Inflammatory Bowel Disease, ulcerative colitis, psoriasis, and Chronic Obstructive Pulmonary Disease (COPD).
  • COPD Chronic Obstructive Pulmonary Disease
  • Stage 1 is characterized by no destructive changes observed upon roentgenographic examination; radiographic evidence of osteoporosis is possible.
  • Stage II moderate progression is characterized by radiographic evidence of periarticular osteoporosis, with or without slight subchondral bone destruction; slight cartilage destruction is possible; joint mobility is possibly limited; no joint deformities are observed; adjacent muscle atrophy is observed; extra-articular soft-tissue lesions (eg, nodules, tenosynovitis) are possible.
  • Stage III severe progression
  • Stage IV terminal progression
  • Stage III is characterized by radiographic evidence of cartilage and bone destruction in addition to periarticular osteoporosis; joint deformity (e.g., subluxation, ulnar deviation, hyperextension) without fibrous or bony ankylosis; extensive muscle atrophy; and extra-articular soft-tissue lesions (eg, nodules, tenosynovitis) are possible.
  • Stage IV terminal progression
  • Remission of RA is defined as ⁇ 5 of the following conditions occurring for at least 2 consecutive months: duration of morning stiffness does not exceed 15 minutes; no fatigue; no joint pain; no joint tenderness or pain with motion; no soft-tissue swelling in joints or tendon sheaths; ESR (erythrocyte sedimentation rate) of less than 30 millimeters/hour (mm/h) in a female or less than 20 mm/h in a male.
  • duration of morning stiffness does not exceed 15 minutes; no fatigue; no joint pain; no joint tenderness or pain with motion; no soft-tissue swelling in joints or tendon sheaths; ESR (erythrocyte sedimentation rate) of less than 30 millimeters/hour (mm/h) in a female or less than 20 mm/h in a male.
  • Functional status of patients with RA is defined as follows: Class I individuals are completely able to perform usual activities of daily living. Class II individuals are able to perform usual self-care and vocational activities but limited in campusional activities. Class III individuals are able to perform usual self-care activities but limited in vocational and mobilizional activities. Class IV individuals are limited in ability to perform usual self-care, vocational, and mobilizional activities.
  • the measurement of differences in the biomarker concentrations, either up- or down-regulated, singly or in combination, in RA patients versus control subjects provides opportunities for better (e.g., simpler, earlier, faster) disease diagnosis, disease staging, risk classification, and/or identification of therapy responders/non-responders.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations or other inflammatory disorder tions for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.
  • the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.
  • the methods pertain to predicting the risk for developing RA.
  • the methods pertain to predicting the risk for developing Crohn's Disease.
  • the methods pertain to predicting the risk for developing Inflammatory Bowel Disease.
  • the methods pertain to predicting the risk for developing ulcerative colitis.
  • the methods pertain to predicting the risk for developing psoriasis.
  • the methods pertain to predicting the risk for developing Chronic Obstructive Pulmonary Disease (COPD).
  • COPD Chronic Obstructive Pulmonary Disease
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1 ⁇ less than healthy volunteer average concentrations for IL-1 ⁇ , a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1 ⁇ less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.
  • the methods pertain to determining the likelihood of developing RA.
  • the methods pertain to determining the likelihood of developing Crohn's Disease.
  • the methods pertain to determining the likelihood of developing Inflammatory Bowel Disease.
  • the methods pertain to determining the likelihood of developing ulcerative colitis.
  • the methods pertain to determining the likelihood of developing psoriasis.
  • the methods pertain to determining the likelihood of developing Chronic Obstructive Pulmonary Disease (COPD).
  • COPD Chronic Obstructive Pulmonary Disease
  • the disclosure provides methods for determining inflammatory disease in a patient.
  • a number of markers can be used to diagnose existing inflammatory disease such as RA.
  • FIGS. 1 , 2 , and 3 show the that patients with elevated levels of IL-17A, IL-17F, and IL-17A/F, either alone or in combination, are likely to be suffering from RA.
  • Other markers such as IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, and cTnI, are also useful in determining disease.
  • the disclosure is provides a method of detecting inflammatory disease by measuring the amount of one or more of IL-17A, IL-17F, IL-17A/F, IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, and cTnI, in a patient sample, comparing the sample to a control population, and determining whether a patient is suffering from inflammatory disease.
  • Statistically significant differences between the patient sample and the control population (healthy volunteers) for one or more markers can be indicative of disease.
  • HV healthy volunteers
  • HV concentrations over
  • the combination of IL-17F & IL-17A, the combination of IL-17A and IL-17 A/F, or the combination of IL-17F and IL-17 A/F can be used as biomarkers in diagnosing RA.
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the patient has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, and a second concentration of one or more
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, and a second concentration of IL-17
  • the disclosure provides methods for identifying RA or other an inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a
  • the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1
  • the methods pertain to identifying an RA patient who responds to therapy.
  • the methods pertain to identifying a Crohn's Disease patient who responds to therapy.
  • the methods pertain to identifying a Inflammatory Bowel Disease patient who responds to therapy.
  • the methods pertain to identifying an ulcerative colitis patient who responds to therapy.
  • the methods pertain to identifying a psoriasis patient who responds to therapy.
  • the methods pertain to identifying a COPD patient who responds to therapy.
  • the disclosure provides methods for predicting the rate of inflammatory disease progression in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the concentration of none or one of IL-17A is greater than 0.18 pg/ml, IL-17-F is greater than 116 pg/ml, or IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one of IL-1 ⁇ is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, or IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a slow rate of inflammatory disease progression.
  • the disclosure provides methods for predicting the rate of inflammatory disease progression, wherein when the concentrations of one of IL-17A is greater than 0.18 pg/ml, the concentration of IL-17-F is greater than 116 pg/ml, and the concentration of IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one or more of IL-1 ⁇ is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, and IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a medium rate of inflammatory disease progression.
  • the disclosure provides methods for predicting the rate of inflammatory disease progression, wherein when the concentrations of one or more of IL-17A is greater than 0.18 pg/ml, the concentration of IL-17-F is greater than 116 pg/ml, and the concentration of IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of at least two of IL-1 ⁇ is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, and IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a high rate of inflammatory disease progression.
  • the disclosure provides methods for predicting the likelihood of inflammatory disease remission in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the concentration of none or one of IL-17A is greater than 0.18 pg/ml, IL-17-F is greater than 116 pg/ml, or IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one of IL-1 ⁇ is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, or IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a high likelihood of inflammatory disease remission.
  • the disclosure provides methods for predicting the likelihood of inflammatory disease remission in a subject, wherein when the concentrations of one of IL-17A is greater than 0.18 pg/ml, the concentration of IL-17-F is greater than 116 pg/ml, and the concentration of IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one or more of IL-1 ⁇ is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, and IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a medium likelihood of inflammatory disease remission.
  • the disclosure provides methods for predicting the likelihood of inflammatory disease remission in a subject, wherein when the concentrations of one or more of IL-17A is greater than 0.18 pg/ml, the concentration of IL-17-F is greater than 116 pg/ml, and the concentration of IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of at least two of IL-1 ⁇ is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, and IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a low likelihood of inflammatory disease remission.
  • the disclosure provides methods for determining the severity of inflammatory disease in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1 ⁇ , IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the concentration of one of IL-17A is greater than 0.18 pg/ml, IL-17-F is greater than 116 pg/ml, or IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of none or one of IL-1 ⁇ is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, or IL-6 is greater than 1.0 pg/ml, the subject is determined to have mild inflammatory disease.
  • the disclosure provides methods for determining the severity of inflammatory disease in a subject, wherein when the concentrations of at least one of IL-17A is greater than 0.18 pg/ml, the concentration of IL-17-F is greater than 116 pg/ml, or the concentration of IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one or more of IL-1 ⁇ is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, and IL-6 is greater than 1.0 pg/ml, the subject is determined to have moderate inflammatory disease.
  • the disclosure provides methods for determining the severity of inflammatory disease in a subject, wherein when the concentrations of at least one of IL-17A is greater than 0.18 pg/ml, the concentration of IL-17-F is greater than 116 pg/ml, and the concentration of IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of two or more of IL-1 ⁇ is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, and IL-6 is greater than 1.0 pg/ml, the subject is determined to have severe inflammatory disease.
  • the inflammatory disease is RA, Crohn's Disease, IBD, ulcerative colitis, psoriasis, or COPD.
  • the inflammatory disease is RA.
  • the inflammatory disease is Crohn's Disease.
  • the inflammatory disease is IBD.
  • the inflammatory disease is ulcerative colitis.
  • the inflammatory disease is psoriasis.
  • the inflammatory disease is COPD.
  • concentrations of biomarkers related to RA or other inflammatory disorder comprise values that are elevated or reduced relative to the concentrations of those same biomarkers in a normal population of subjects (e.g., the HV group as provided herein).
  • concentrations of biomarkers related to RA or other inflammatory disorder comprise values that are elevated or reduced relative to the concentrations of those same biomarkers in a normal population of subjects (e.g., the HV group as provided herein).
  • One of skill in the art may also measure biomarker concentrations in one or more HV populations utilizing an apparatus capable of sensitively measuring the concentrations of biomarkers described herein and calculate the average values for each biomarker in such HV populations.
  • the sample can be a single sample from the subject.
  • the sample can be a series of samples taken at various points in time so that changes in concentration over time of biomarker related to RA or other inflammatory disorder can be identified and interpreted.
  • the samples can be taken in over the course of hours, days, weeks, months, and years. The samples can be taken at any regular or irregular interval based on the detected concentration(s) of biomarker related to RA or other inflammatory disorder and/or the change in the concentration(s) of biomarker related to RA or other inflammatory disorder in the one or more samples over time.
  • such information can be taken from any known clinical study or database that maintains such patient samples and/or patient history.
  • the diagnostic/prognostic methods described herein generally involve the determination of the amount of biomarker related to RA or other inflammatory disorder from one or a set of samples from a subject. Determination of concentrations of biomarker related to RA or other inflammatory disorder in the practice of the methods can be performed using any suitable apparatus or system that allow for the detection levels described herein.
  • suitable apparatus includes, but is not limited to, the systems described in Published U.S. Patent Application Nos: 2009/0159812 (Livingston); 2008/0003685 (Goix, et al.); and U.S. Pat. No. 7,572,640, all incorporated herein by reference.
  • U.S. Pat. No. 7,572,640 describes instruments, reagents and methods for measuring analytes at levels to carry out this invention and thus identify those patients with of biomarker related to RA levels above or below the normal HV range.
  • cTnI assays 100 ul of paramagnetic microparticles, and 150 ul for cTnI assays (MPs, MyOne, Invitrogen Dynal AS; approximately 5-10 ug MPs/well), coated with the capture antibody and diluted in assay buffer (1% BSA, Tris-buffered saline, pH 7.4, with 0.5 mL Triton X-100/L, and heterophile/human antimouse antibody-blocking reagents (from Scantibodies Laboratories, used per the manufacturer's recommendations)), were added to each well and incubated for about 2 hours (about 1 hour for cTnI and IL-1 ⁇ ). MPs were separated using a magnetic bed (Ambion).
  • cTnI Cardiac Troponin-I
  • IL-17F was elevated in RA patients compared to matched controls. This is the first time that anyone has found IL-17F to be elevated in RA.
  • Il-17A was found to be elevated in RA patients. Although the increase in IL-17A was modest (approximately 3-fold) it was highly statistically significant. This is the first time that Il-17A has been shown to be elevated in RA patients compared to controls in plasma and furthermore the magnitude of the elevation was modest and at a low concentration (average approx 1 pg/mL).
  • IL-6 was found elevated in RA patients versus controls. It has been previously shown that IL-6 is elevated in RA patients; however, it has never been shown that IL-6 elevation correlates with elevations of Il-7A, IL-17F, IL-17A/F, and/or cTnI in some subjects and does not correlate with such elevations in other subjects.
  • IL-1 ⁇ was shown to be decreased in RA patients. This is the first time that this serum biomarker has been shown to be down-regulated in RA.
  • the measurement of differences in the biomarker concentrations, either up- or down-regulated, singly or in combination, in RA patients versus control subjects provides opportunities for better (e.g., simpler, earlier, faster) disease diagnosis, disease staging, risk classification, disease progression, disease severity and/or identification of therapy responders/non-responders.
  • Table 6 shows AuROC as a measure of predictive power for RA.
  • AuROC does not depend on specifying a cut-point and can be interpreted as the probability that a random RA patient will be classified correctly.
  • AuROC>0.8 suggests very good performance. Odds ratios require specification of a somewhat arbitrary cut-point, wherein the large CIs show the uncertainty in the odds ratios caused by small sample size.
  • any numerical values recited herein include all values from the lower value to the upper value in increments of one unit provided that there is a separation of at least two units between any lower value and any higher value.
  • concentration of a component or value of a process variable such as, for example, size, angle size, pressure, time and the like, is, for example, from 1 to 90, specifically from 20 to 80, more specifically from 30 to 70, it is intended that values such as 15 to 85, 22 to 68, 43 to 51, 30 to 32, etc. are expressly enumerated in this specification.
  • one unit is considered to be 0.0001, 0.001, 0.01 or 0.1 as appropriate.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US13/102,683 2010-05-06 2011-05-06 Methods for Diagnosing, Staging, Predicting Risk for Developing and Identifying Treatment Responders for Rheumatoid Arthritis Abandoned US20110301053A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/102,683 US20110301053A1 (en) 2010-05-06 2011-05-06 Methods for Diagnosing, Staging, Predicting Risk for Developing and Identifying Treatment Responders for Rheumatoid Arthritis
US14/476,820 US10288623B2 (en) 2010-05-06 2014-09-04 Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33208110P 2010-05-06 2010-05-06
US201061428500P 2010-12-30 2010-12-30
US201161444702P 2011-02-19 2011-02-19
US13/102,683 US20110301053A1 (en) 2010-05-06 2011-05-06 Methods for Diagnosing, Staging, Predicting Risk for Developing and Identifying Treatment Responders for Rheumatoid Arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/476,820 Continuation US10288623B2 (en) 2010-05-06 2014-09-04 Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis

Publications (1)

Publication Number Publication Date
US20110301053A1 true US20110301053A1 (en) 2011-12-08

Family

ID=44904110

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/102,683 Abandoned US20110301053A1 (en) 2010-05-06 2011-05-06 Methods for Diagnosing, Staging, Predicting Risk for Developing and Identifying Treatment Responders for Rheumatoid Arthritis
US14/476,820 Expired - Fee Related US10288623B2 (en) 2010-05-06 2014-09-04 Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/476,820 Expired - Fee Related US10288623B2 (en) 2010-05-06 2014-09-04 Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis

Country Status (6)

Country Link
US (2) US20110301053A1 (cg-RX-API-DMAC7.html)
EP (1) EP2566971B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013525820A (cg-RX-API-DMAC7.html)
AU (1) AU2011249908A1 (cg-RX-API-DMAC7.html)
CA (1) CA2798149A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011140484A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130261016A1 (en) * 2012-03-28 2013-10-03 Meso Scale Technologies, Llc Diagnostic methods for inflammatory disorders
US12618858B2 (en) 2020-08-07 2026-05-05 Vital Biosciences Inc. Kinetic modulation for magnetic analyte detection

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071298A (en) 1974-06-27 1978-01-31 Stanford Research Institute Laser Raman/fluorescent device for analyzing airborne particles
DE2732272C2 (de) 1977-07-16 1979-07-05 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, 6900 Heidelberg Verfahren und Vorrichtung zur Fluoreszenzanalyse von gefärbten Partikeln, insbesondere biologischen Zellen
US4251733A (en) 1978-06-29 1981-02-17 Hirleman Jr Edwin D Technique for simultaneous particle size and velocity measurement
US4172227A (en) 1978-07-21 1979-10-23 Becton, Dickinson And Company Flow microfluorometer
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4521733A (en) 1983-05-23 1985-06-04 General Electric Company NMR Imaging of the transverse relaxation time using multiple spin echo sequences
US4768879A (en) 1986-06-17 1988-09-06 The Dow Chemical Company Method for measuring the size of objects in a fluid medium
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4988191A (en) 1987-03-09 1991-01-29 University Of Illinois Electro-optical method and system for determining the direction of motion in double-exposure velocimetry by shifting an optical image field
US5041733A (en) 1987-03-20 1991-08-20 Agency Of Industrial Science & Technology Method and apparatus for identifying chromosomes or cells
DE3720844A1 (de) 1987-06-24 1989-01-05 Stefan Miltenyi Trennsaeule fuer die magnetische separierung von zellen, zellaggregaten, und zellulaeren bestandteilen
US4793705A (en) 1987-10-07 1988-12-27 The United States Of America As Represented By The United States Department Of Energy Single molecule tracking
US4927265A (en) 1988-04-29 1990-05-22 501 Microphoretic Systems, Inc. Detector for fluorescence and absorption spectroscopy
US4972265A (en) 1988-05-06 1990-11-20 Minolta Camera Kabushiki Kaisha Electronic camera having a controllable light blocking member
US5002389A (en) 1988-12-22 1991-03-26 Honeywell Inc. Pulsed fluorescence velocimeter
US5385707A (en) 1988-12-28 1995-01-31 Stefan Miltenyi Metal matrices for use in high gradient magnetic separation of biological materials and method for coating the same
US4979824A (en) 1989-05-26 1990-12-25 Board Of Trustees Of The Leland Stanford Junior University High sensitivity fluorescent single particle and single molecule detection apparatus and method
US5108179A (en) 1989-08-09 1992-04-28 Myers Stephen A System and method for determining changes in fluorescence of stained nucleic acid in electrophoretically separated bands
US5274240A (en) 1990-01-12 1993-12-28 The Regents Of The University Of California Capillary array confocal fluorescence scanner and method
US5770029A (en) 1996-07-30 1998-06-23 Soane Biosciences Integrated electrophoretic microdevices
CA2079005A1 (en) 1990-04-11 1991-10-12 Geoffrey Stephen Begg Methods and apparatus allowing sequential chemical reactions
US5094594A (en) 1990-04-23 1992-03-10 Genomyx, Incorporated Piezoelectric pumping device
US5230997A (en) 1990-07-19 1993-07-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of detecting the presence of human herpesvirus-7 infection
US5269937A (en) 1990-10-23 1993-12-14 Cetus Corporation HPLC light scattering detector for biopolymers
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5846708A (en) 1991-11-19 1998-12-08 Massachusetts Institiute Of Technology Optical and electrical methods and apparatus for molecule detection
US5290834A (en) 1991-12-04 1994-03-01 Rohm & Haas Company Method for controlling elution rate of agent
US5209834A (en) 1992-03-09 1993-05-11 The United States Of America As Represented By The United States Department Of Energy Ordered transport and identification of particles
AU5884394A (en) 1993-01-18 1994-08-15 Evotec Biosystems Gmbh Method and device for assessing the suitability of biopolymers
GB9301122D0 (en) 1993-01-21 1993-03-10 Scient Generics Ltd Method of analysis/separation
US5547849A (en) 1993-02-17 1996-08-20 Biometric Imaging, Inc. Apparatus and method for volumetric capillary cytometry
JPH06265447A (ja) 1993-03-16 1994-09-22 Hitachi Ltd 微量反応装置およびこれを使用する微量成分測定装置
US5543838A (en) 1993-08-31 1996-08-06 Xerox Corporation Signal multiplexing system for an image sensor array
JP3290786B2 (ja) 1993-11-26 2002-06-10 シスメックス株式会社 粒子分析装置
DE4405005A1 (de) 1994-02-17 1995-08-24 Rossendorf Forschzent Mikro-Fluiddiode
US5540494A (en) 1994-06-03 1996-07-30 Purvis, Jr.; Norman B. Method and apparatus for determining absolute particle size, surface area and volume normalized fluorescence using forward angle light scatter intensity in flow cytometry
US6001229A (en) 1994-08-01 1999-12-14 Lockheed Martin Energy Systems, Inc. Apparatus and method for performing microfluidic manipulations for chemical analysis
US5571410A (en) 1994-10-19 1996-11-05 Hewlett Packard Company Fully integrated miniaturized planar liquid sample handling and analysis device
US5645702A (en) 1995-06-07 1997-07-08 Hewlett-Packard Company Low voltage miniaturized column analytical apparatus and method
US5658413A (en) 1994-10-19 1997-08-19 Hewlett-Packard Company Miniaturized planar columns in novel support media for liquid phase analysis
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5603351A (en) 1995-06-07 1997-02-18 David Sarnoff Research Center, Inc. Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device
FI98765C (fi) 1995-01-16 1997-08-11 Erkki Soini Virtaussytometrinen menetelmä ja laite
DE19508366C2 (de) 1995-03-10 1998-01-29 Evotec Biosystems Gmbh Verfahren zum direkten Nachweisen weniger Nucleinsäurestränge
US5793485A (en) 1995-03-20 1998-08-11 Sandia Corporation Resonant-cavity apparatus for cytometry or particle analysis
US5682038A (en) 1995-04-06 1997-10-28 Becton Dickinson And Company Fluorescent-particle analyzer with timing alignment for analog pulse subtraction of fluorescent pulses arising from different excitation locations
US6991907B1 (en) 1995-04-18 2006-01-31 Biosite, Inc. Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays
DE19524572A1 (de) 1995-07-06 1997-01-09 Bayer Ag Verfahren zur Herstellung eines synthetischen Kalibrators für den Einsatz in Immunoassays, bestehend aus den Analyten oder Teilsequenzen davon, die an inerten Trägermoleküle konjugiert sind
US5798222A (en) 1995-07-17 1998-08-25 Guava Technologies, Inc. Apparatus for monitoring substances in organisms
US6132580A (en) 1995-09-28 2000-10-17 The Regents Of The University Of California Miniature reaction chamber and devices incorporating same
US5716825A (en) 1995-11-01 1998-02-10 Hewlett Packard Company Integrated nucleic acid analysis system for MALDI-TOF MS
DE19548028A1 (de) 1995-12-21 1997-06-26 Bayer Ag Verfahren zur Herstellung eines synthetischen Kalibrators für den Einsatz in Sandwich-Immunoassays, bestehend aus einem Antikörper gegen einen der im Assay benutzten Antikörper und einer Sequenz des Analyten
US5746901A (en) 1996-04-05 1998-05-05 Regents Of The University Of California Hybrid slab-microchannel gel electrophoresis system
US6399023B1 (en) 1996-04-16 2002-06-04 Caliper Technologies Corp. Analytical system and method
US5795758A (en) 1997-04-18 1998-08-18 Smithkline Beecham Corporation DNA encoding histidyl tRNA synthetase variant from Streptococcus pneumoniae
US5863801A (en) 1996-06-14 1999-01-26 Sarnoff Corporation Automated nucleic acid isolation
DE19630956A1 (de) 1996-07-31 1998-02-05 Basf Ag Verfahren und Vorrichtung zur Raman-Korrelationsspektroskopie
DE19634873A1 (de) 1996-08-29 1998-03-12 Boehringer Mannheim Gmbh System zur Unterscheidung fluoreszierender Molekülgruppen durch zeitaufgelöste Fluoreszenzmessung
DE19647927A1 (de) 1996-11-20 1998-05-28 Bayer Ag Verfahren zur Herstellung einer stabilen Troponin I Präparation und dessen Verwendung als Kalibrator in Immunoassays
DE19649048C1 (de) 1996-11-27 1998-04-09 Evotec Biosystems Gmbh Verfahren zur Unterscheidung oder Erfassung von Partikeln in einer Probe durch Identifizierung von Signalabschnitten zeitaufgelöster, optischer Rohsignale aus der Probe auf Basis von Einzelphotonendetektion
US5795158A (en) 1996-12-02 1998-08-18 Warinner; Peter Apparatus to review clinical microbiology
IL156002A0 (en) 1997-02-12 2003-12-23 Eugene Y Chan Methods and products for analyzing polymers
CA2284870C (en) 1997-03-17 2003-11-25 Tsi Incorporated System for detecting fluorescing components in aerosols
US6235471B1 (en) 1997-04-04 2001-05-22 Caliper Technologies Corp. Closed-loop biochemical analyzers
US5985214A (en) 1997-05-16 1999-11-16 Aurora Biosciences Corporation Systems and methods for rapidly identifying useful chemicals in liquid samples
US6710871B1 (en) 1997-06-09 2004-03-23 Guava Technologies, Inc. Method and apparatus for detecting microparticles in fluid samples
GB2326229A (en) 1997-06-13 1998-12-16 Robert Jeffrey Geddes Carr Detecting and analysing submicron particles
US5989402A (en) 1997-08-29 1999-11-23 Caliper Technologies Corp. Controller/detector interfaces for microfluidic systems
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6143152A (en) 1997-11-07 2000-11-07 The Regents Of The University Of California Microfabricated capillary array electrophoresis device and method
US6049380A (en) 1997-11-12 2000-04-11 Regents Of The University Of California Single molecule identification using selected fluorescence characteristics
WO1999026067A1 (en) 1997-11-18 1999-05-27 Bio-Rad Laboratories, Inc. Multiplex flow immunoassays with magnetic particles as solid phase
US6041515A (en) 1998-01-12 2000-03-28 Life Technologies, Inc. Apparatus for drying solutions containing macromolecules
SE9800360D0 (sv) 1998-02-06 1998-02-06 Goeteborg University Science I Method, apparatus and flow cell for high sensitivity detection of fluorescent molecules
DE19822452C2 (de) 1998-04-22 2003-02-13 Stefan Seeger Verfahren zur Bestimmung der Dichte lumineszierender Moleküle an einer Oberfläche, Verwendung des Verfahrens zur Bestimmung von Adsorptions- und Bindungskinetiken und Gleichgewichts- und Bindungskonstanten von Molekülen an einer Oberfläche durch Lumineszenz-Messungen und Vorrichtung zur Durchführung des Verfahrens
EP0955084B1 (en) 1998-04-27 2006-07-26 Corning Incorporated Method of depositing an array of biological samples using a redrawn capillary reservoir
US6689323B2 (en) 1998-10-30 2004-02-10 Agilent Technologies Method and apparatus for liquid transfer
US6361671B1 (en) 1999-01-11 2002-03-26 The Regents Of The University Of California Microfabricated capillary electrophoresis chip and method for simultaneously detecting multiple redox labels
JP2000208208A (ja) 1999-01-18 2000-07-28 Sony Corp コネクタ装置及びそれを用いた電子機器並びにプラグ
US6671044B2 (en) 1999-01-25 2003-12-30 Amnis Corporation Imaging and analyzing parameters of small moving objects such as cells in broad flat flow
US6473176B2 (en) 1999-01-25 2002-10-29 Amnis Corporation Imaging and analyzing parameters of small moving objects such as cells
US6249341B1 (en) 1999-01-25 2001-06-19 Amnis Corporation Imaging and analyzing parameters of small moving objects such as cells
DE19909326A1 (de) 1999-03-03 2000-09-21 Lucas Ind Plc Vorrichtung und Verfahren zum Steuern der Fahrgeschwindigkeit eines Kraftfahrzeuges
US6403947B1 (en) 1999-03-18 2002-06-11 Cambridge Research & Instrumentation Inc. High-efficiency multiple probe imaging system
US6242266B1 (en) 1999-04-30 2001-06-05 Agilent Technologies Inc. Preparation of biopolymer arrays
WO2000070080A1 (en) 1999-05-17 2000-11-23 Caliper Technologies Corp. Focusing of microparticles in microfluidic systems
US6309886B1 (en) 1999-06-04 2001-10-30 The Regents Of The University Of California High throughput analysis of samples in flowing liquid
US6811668B1 (en) 1999-06-22 2004-11-02 Caliper Life Sciences, Inc. Apparatus for the operation of a microfluidic device
US6338746B1 (en) 1999-07-23 2002-01-15 Rlc Technologies, L.L.C. Polymer-sulfur-polymer coated fertilizers
US6532067B1 (en) 1999-08-09 2003-03-11 The United States Of America As Represented By The Secretary Of The Army Aerosol fluorescence spectrum analyzer for rapid measurement of single airborne particles
US6495104B1 (en) 1999-08-19 2002-12-17 Caliper Technologies Corp. Indicator components for microfluidic systems
AU7747600A (en) 1999-10-01 2002-05-15 University Of California, The Microfabricated liquid sample loading system
US6296452B1 (en) 2000-04-28 2001-10-02 Agilent Technologies, Inc. Microfluidic pumping
US20020167665A1 (en) 2000-05-19 2002-11-14 Yeung Edward S. High-throughput methods of distinguishing at least one molecule individually in a sample comprising multiple molecules and systems for use therein
US6608680B2 (en) 2000-08-25 2003-08-19 Amnis Corporation TDI imaging system for kinetic studies
EP2325263B1 (en) 2000-09-29 2013-01-23 Life Technologies Corporation Modified carbocyanine dyes and their conjugates
US6537437B1 (en) 2000-11-13 2003-03-25 Sandia Corporation Surface-micromachined microfluidic devices
US6783992B2 (en) 2001-01-03 2004-08-31 Agilent Technologies, Inc. Methods and using chemico-mechanical microvalve devices for the selective separation of components from multi-component fluid samples
EP1221678A1 (fr) 2001-01-09 2002-07-10 Telectronic SA Récepteur destiné à capter un signal électromagnétique et dispositif utilisant un tel récepteur
US6850317B2 (en) 2001-01-23 2005-02-01 Schlumberger Technology Corporation Apparatus and methods for determining velocity of oil in a flow stream
US6386219B1 (en) 2001-02-01 2002-05-14 Agilent Technologies, Inc. Fluid handling system and method of manufacture
US6949377B2 (en) 2001-03-05 2005-09-27 Ho Winston Z Chemiluminescence-based microfluidic biochip
US6802342B2 (en) 2001-04-06 2004-10-12 Fluidigm Corporation Microfabricated fluidic circuit elements and applications
EP1322957B1 (en) 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
DE60226864D1 (de) * 2001-05-23 2008-07-10 Boehringer Ingelheim Pharma Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US6766817B2 (en) 2001-07-25 2004-07-27 Tubarc Technologies, Llc Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action
US20040219509A1 (en) 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US6394305B1 (en) 2001-08-31 2002-05-28 Beverly Sydlosky Food holder and lifter with adjustable handles
US6867005B2 (en) 2001-10-24 2005-03-15 Beckman Coulter, Inc. Method and apparatus for increasing the dynamic range and accuracy of binding assays
CA2463420A1 (en) 2001-10-24 2003-05-01 Singulex, Inc. Methods for detecting genetic haplotypes by interaction with probes
US6599436B1 (en) 2001-12-06 2003-07-29 Sandia Corporation Formation of interconnections to microfluidic devices
AU2003224953A1 (en) 2002-04-11 2003-10-27 Bristol-Myers Squibb Company Mass spectrometer autosampler
MXPA03004105A (es) 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
US20050164205A1 (en) 2002-11-19 2005-07-28 Singulex, Inc. Charge and mass tags for detection and analysis
JP2006526140A (ja) 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
EP1586068B1 (en) 2003-01-23 2008-07-30 U.S. Genomics, Inc. Methods for analyzing polymer populations
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
US7074194B2 (en) 2003-05-19 2006-07-11 Ischemia Technologies, Inc. Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin
DK1641822T3 (da) * 2003-07-08 2013-07-22 Genentech Inc Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
US7547518B2 (en) 2003-08-19 2009-06-16 Becton, Dickinson And Company Method of screening endothelial cells for angiogenic capability
EP2280286A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
EP1711622A2 (en) 2003-11-26 2006-10-18 Applera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
WO2005089524A2 (en) 2004-03-19 2005-09-29 U.S. Genomics, Inc. Compositions and methods for detection of single molecules
WO2006036388A2 (en) 2004-08-23 2006-04-06 U.S. Genomics, Inc. Systems and methods for detecting and analyzing polymers
EP1805500A4 (en) 2004-09-28 2008-05-07 Singulex Inc SYSTEM AND METHOD FOR THE SPECTROSCOPIC ANALYSIS OF INDIVIDUAL PARTICLES
US8685711B2 (en) 2004-09-28 2014-04-01 Singulex, Inc. Methods and compositions for highly sensitive detection of molecules
US9040305B2 (en) 2004-09-28 2015-05-26 Singulex, Inc. Method of analysis for determining a specific protein in blood samples using fluorescence spectrometry
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
WO2006098772A2 (en) 2004-10-13 2006-09-21 U.S. Genomics, Inc. Systems and methods for measurement optimization
CN101218254A (zh) * 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
US20070249533A1 (en) * 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
DE602006021768D1 (de) 2005-09-28 2011-06-16 Dickinson & Co Nachweis von lysophosphatidylcholin für die prognose oder diagnose eines systemischen entzündungszustands
US20070259377A1 (en) 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
WO2008039553A1 (en) 2006-02-10 2008-04-03 Zymogenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
AU2007233320B2 (en) 2006-04-04 2013-12-12 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP1887361A1 (en) 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
AU2008352940B2 (en) 2007-12-19 2014-06-05 Singulex, Inc. Scanning analyzer for single molecule detection and methods of use
CN102016552A (zh) * 2008-03-05 2011-04-13 神谷来克斯公司 用于分子的高灵敏性检测的方法和组合物
BRPI0908312A2 (pt) * 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
JP2010071833A (ja) * 2008-09-19 2010-04-02 Kyoto Univ 関節リウマチ疾患の検査方法および検査用キット

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Alex et al, Clinical and Experimental Rheumatology 2007; Vol. 25, pages 584-592. *
Barnes et al, American Journal of Respiratory Cell and Molecular Biology, August 2009, vol. 41, pages 631-638. *
Brynskov et al, Gut, 1992, Vol. 33, pages 55-58. *
Erenna® IL-17A Immunoassay Kit data sheet, 2006. *
Erenna® IL-1beta Immunoassay Kit, 2006. *
Schultze et al, Toxicologic Pathology, 2008, Vol. 36, pages 777-782. *
Tchetverikov et al, Annual Rheumatology Disease, 2004, Vol. 63, pages 881-883. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130261016A1 (en) * 2012-03-28 2013-10-03 Meso Scale Technologies, Llc Diagnostic methods for inflammatory disorders
US12618858B2 (en) 2020-08-07 2026-05-05 Vital Biosciences Inc. Kinetic modulation for magnetic analyte detection

Also Published As

Publication number Publication date
US20150119275A1 (en) 2015-04-30
EP2566971B1 (en) 2019-03-27
EP2566971A1 (en) 2013-03-13
CA2798149A1 (en) 2011-11-10
AU2011249908A1 (en) 2012-11-22
WO2011140484A1 (en) 2011-11-10
US10288623B2 (en) 2019-05-14
EP2566971A4 (en) 2013-12-25
JP2013525820A (ja) 2013-06-20

Similar Documents

Publication Publication Date Title
CN102782501B (zh) 在无症状患者中基于il-6检测的全身炎性应答综合征和败血症的早期诊断和预测
JP5931200B2 (ja) L−fabpに基づく、急性事象後または外科的介入後の腎障害の診断
EP2467724B1 (en) Survival prognostic assay
US11041864B2 (en) Method for prediction of prognosis of sepsis
zur Wiesch et al. Pediatric rheumatology Myeloid related proteins MRP8/MRP14 may predict disease flares in juvenile idiopathic arthritis
CN105556308A (zh) 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物
US20220011311A1 (en) Detection of bladder cancer
US10288623B2 (en) Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis
WO2003069349A2 (en) Method for diagnosis of inflammatory diseases using mrp8/mrp14
US20240402176A1 (en) Detection of bladder cancer in males
US10094826B2 (en) Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-PIK3CD
JP7614477B2 (ja) 間質性肺炎のタンパク質診断バイオマーカー
US20130252265A1 (en) Method for testing for cerebral infarction via cartilage acidic protein 1
JP4354954B2 (ja) 関節リウマチの検出又は鑑別方法及び病期又は機能障害度の判別方法
Ali et al. Nephroblastoma-overexpressed protein as a prognostic marker for high disease activity in Iraqi patients with rheumatoid arthritis
JP2010071833A (ja) 関節リウマチ疾患の検査方法および検査用キット
Sari et al. The Value of the TB IgG/IgM Rapid Test and Erythrocyte Sedimentation Rate in Relation to Xpert MTB/RIF Tests in the Diagnosis of Pulmonary Tuberculosis
JP7640168B2 (ja) 夜尿症の患者の治療応答を予測する方法
WO2013107745A1 (en) Method for predicting a risk of increased mortality
Kadim et al. Investigate the levels of soluble vascular cell adhesion molecule 1 (sVCAM-1) and intercellular adhesion molecule 1 (sICAM-1) in the sera of patients with rheumatoid arthritis
Gilliam et al. Pediatric rheumatology. Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study
HK1200216B (en) L-fabp based diagnosis of kidney injury after an acute event or after a surgical intervention
JP2015111050A (ja) Kallistatin蛋白質による脳梗塞検査方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: SINGULEX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TODD, JOHN ALLAN;LU, QUYNH ANH THUC;LE, SARA JANE;SIGNING DATES FROM 20110809 TO 20110822;REEL/FRAME:026801/0483

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION